Emily Whitehead made the history books in 2012 when she become the first pediatric patient with B-cell acute lymphoblastic leukemia to be given a chimeric antigen receptor (CAR) T-cell therapy. After ...

Legend Biotech (NASDAQ:LEGN) reports today. Explore the key operating questions around cell-therapy demand and manufacturing, ...

It's an exciting time to be in cell therapy manufacturing and commercialization, particularly in the oncology space. This year alone, we've seen the US approval of three cell therapy products: Iovance ...

While Kite Pharma has partnered with Cytiva to develop a new cell therapy manufacturing platform, which was rolled out last month, the Gilead Sciences subsidiary isn’t stopping there in its pursuit of ...

Bristol Myers Squibb was the first major biopharma company to take notice of innovative cell therapy contract manufacturer Cellares, participating in a $255 million series C funding round in August of ...

Add Yahoo as a preferred source to see more of our stories on Google. FDA commissioner Marty Makary said eased manufacturing requirements for certain cell and gene therapies were “common-sense reforms ...

The FDA’s May 2026 guidance on cell and gene therapies provides for CMC flexibilities while insisting on quality and ...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off the shelf”, cell therapies for serious medical conditions, ...

The AMT designation gives Cellares’ clients using the Cell Shuttle priority review with the FDA leading to accelerated regulatory filings SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the ...

Human pluripotent stem cells (hPSCs) have long been viewed as one of regenerative medicine’s most promising raw materials. Now, as more than 100 clinical trials evaluate hPSC-derived therapies for ...